BriaCell Therapeutics Files 8-K
Ticker: BCTXZ · Form: 8-K · Filed: Sep 11, 2024 · CIK: 1610820
Sentiment: neutral
Topics: corporate-event, financial-reporting
Related Tickers: BCTX
TL;DR
BriaCell Therapeutics filed an 8-K on 9/11/24, reporting on corporate events and financials as of 9/9/24.
AI Summary
BriaCell Therapeutics Corp. filed an 8-K on September 11, 2024, reporting other events and financial statements as of September 9, 2024. The company, formerly known as Ansell Capital Corp., is incorporated in British Columbia and operates in the pharmaceutical preparations sector.
Why It Matters
This filing provides an update on the company's corporate activities and financial reporting, which is important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, indicating no immediate significant events or changes.
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Registrant
- Ansell Capital Corp. (company) — Former company name
- September 9, 2024 (date) — Date of earliest event reported
- September 11, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of September 9, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on September 9, 2024.
What was BriaCell Therapeutics Corp. formerly known as?
BriaCell Therapeutics Corp. was formerly known as Ansell Capital Corp.
In which jurisdiction is BriaCell Therapeutics Corp. incorporated?
BriaCell Therapeutics Corp. is incorporated in British Columbia.
What is the Standard Industrial Classification code for BriaCell Therapeutics Corp.?
The Standard Industrial Classification code for BriaCell Therapeutics Corp. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 560 words · 2 min read · ~2 pages · Grade level 9.4 · Accepted 2024-09-11 08:50:12
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex99-1.htm (EX-99.1) — 15KB
- ex99-2.htm (EX-99.2) — 18KB
- ex99-3.htm (EX-99.3) — 37KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- ex99-2_001.jpg (GRAPHIC) — 4KB
- ex99-3_001.jpg (GRAPHIC) — 4KB
- 0001493152-24-035737.txt ( ) — 363KB
- bctx-20240909.xsd (EX-101.SCH) — 4KB
- bctx-20240909_def.xml (EX-101.DEF) — 29KB
- bctx-20240909_lab.xml (EX-101.LAB) — 36KB
- bctx-20240909_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated September 9, 2024. 99.2 Press Release, dated September 10, 2024. 99.3 Press Release, dated September 11, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRIACELL THERAPEUTICS CORP. /s/ William V. Williams September 11, 2024 William V. Williams President and Chief Executive Officer